Jun Li
Jun Li
1
Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
2
Henan Key Laboratory of Molecular Pathology, Zhengzhou, China
1,2,†,
Sile Han
Sile Han
1
Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
1,†,
Cuiyun Zhang
Cuiyun Zhang
1
Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
2
Henan Key Laboratory of Molecular Pathology, Zhengzhou, China
1,2,
Yanlin Luo
Yanlin Luo
3
Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
3,
Li Wang
Li Wang
3
Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
3,
Ping Wang
Ping Wang
4
Department of Pathophysiology, School of Basic Medical Science, Zhengzhou University, Zhengzhou, China
4,
Yi Wang
Yi Wang
5
Department of Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
5,
Qingxin Xia
Qingxin Xia
5
Department of Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
5,
Xiaoyan Wang
Xiaoyan Wang
1
Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
2
Henan Key Laboratory of Molecular Pathology, Zhengzhou, China
1,2,
Bing Wei
Bing Wei
1
Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
2
Henan Key Laboratory of Molecular Pathology, Zhengzhou, China
1,2,
Jie Ma
Jie Ma
1
Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
2
Henan Key Laboratory of Molecular Pathology, Zhengzhou, China
1,2,
Hongle Li
Hongle Li
1
Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
2
Henan Key Laboratory of Molecular Pathology, Zhengzhou, China
1,2,*,
Yongjun Guo
Yongjun Guo
1
Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
2
Henan Key Laboratory of Molecular Pathology, Zhengzhou, China
1,2,*
1
Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
2
Henan Key Laboratory of Molecular Pathology, Zhengzhou, China
3
Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
4
Department of Pathophysiology, School of Basic Medical Science, Zhengzhou University, Zhengzhou, China
5
Department of Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
✉*Correspondence: Yongjun Guo, guoyongjun@zzu.edu.cn; Hongle Li, llhl73@163.com
This article was submitted to Gynecological Oncology, a section of the journal Frontiers in Oncology
†These authors have contributed equally to this work and share first authorship
Received 2021 Dec 21; Accepted 2021 Dec 22; Collection date 2021.
Keywords: BRCA1/2, haplotype analysis, ovarian cancer, founder mutation, Chinese
Copyright © 2022 Li, Han, Zhang, Luo, Wang, Wang, Wang, Xia, Wang, Wei, Ma, Li and Guo
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.